Department of Neurology, West China Hospital, Sichuan University, No. 37 Guoxue Road, Chengdu, Sichuan 610041, China.
Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Mult Scler Relat Disord. 2023 Feb;70:104495. doi: 10.1016/j.msard.2022.104495. Epub 2022 Dec 30.
To assess safety data of the inactivated COVID-19 vaccines in a real-world sample of people with autoimmune encephalitis (pwAE).
A cross-sectional study was performed between 1 March and 30 April 2022. We invited pwAE from our previous ONE-WC (Outcome of Autoimmune Encephalitis Study in Western China) registration study database, to attend neurological clinics, at West China Hospital to participate in a face-to-face survey using a custom-designed questionnaire for this study. The ONE-WC study began in October 2011 and prospectively enrolled pwAE from four large comprehensive neurological centers in Sichuan province, China.
Of the 387 pwAE, 240 (62.0%) completed the questionnaire. Half the 240 participants (121, 50.4%) reported receiving at least one dose of COVID-19 vaccine, which in all but two patients received inactivated COVID-19 vaccine. Among vaccinated pwAE, the median age was 35 years (range 15-69) and 57.8% of them were women. The most frequent reasons that unvaccinated individuals reported for not receiving the COVID-19 vaccine were concern about vaccine-induced relapse of AE (50.4%) and advice from a physician to delay vaccination (21.0%). Small proportions of vaccinated individuals reported adverse events after the first dose (11.5%) or the second dose (10.2%), and none of the adverse events was serious. Across the entire sample, one individual reported relapsing within 30 days after the first dose and three individuals reported relapsing more than 120 days after the first dose.
This real-world survey indicates an overall favorable safety profile of the inactivated COVID-19 vaccine for pwAE.
评估在自身免疫性脑炎（pwAE）患者的真实世界样本中使用灭活 COVID-19 疫苗的安全性数据。
在 2022 年 3 月 1 日至 4 月 30 日期间进行了一项横断面研究。我们邀请了来自之前的 ONE-WC（中国西部自身免疫性脑炎研究的结果）登记研究数据库的 pwAE，参加华西医院的神经科诊所，使用为本研究设计的定制问卷进行面对面调查。ONE-WC 研究始于 2011 年 10 月，前瞻性地招募了来自中国四川省四个大型综合神经中心的 pwAE。
在 387 名 pwAE 中，有 240 名（62.0%）完成了问卷。240 名参与者中有一半（121 名，50.4%）报告至少接种了一剂 COVID-19 疫苗，所有参与者均接种了灭活 COVID-19 疫苗，除了两名患者。在接种疫苗的 pwAE 中，中位年龄为 35 岁（范围 15-69），其中 57.8%为女性。未接种疫苗的个体报告未接种 COVID-19 疫苗的最常见原因是担心疫苗引起 AE 复发（50.4%）和医生建议推迟接种（21.0%）。少数接种疫苗的个体报告在第一剂或第二剂后出现不良反应（11.5%和 10.2%），但没有严重的不良反应。在整个样本中，有 1 名个体在第一剂后 30 天内复发，有 3 名个体在第一剂后 120 天以上复发。
这项真实世界的调查表明，灭活 COVID-19 疫苗在 pwAE 中的总体安全性良好。
